Search research articles
Contact Us
Filters
Showing results (271-280 of 293) with videos related to
Page
of 30
Sort By:
Hepatobiliary Surgery and Nutrition
|
June 9, 2020
Systemic therapy without radiation may be appropriate as neoadjuvant therapy for localized pancreas cancer
Scott Kizy, Ariella M Altman, Keith M Wirth, et al.
Annals of Surgery
|
April 1, 2020
Bariatric Surgery is Associated With Decreased Progression of Nonalcoholic Fatty Liver Disease to Cirrhosis: A Retrospective Cohort Analysis
Keith M Wirth, Adam C Sheka, Scott Kizy, et al.
Urology
|
August 8, 2001
Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression
M Wirth, C Tyrrell, M Wallace, et al.
Der Urologe. Ausg. A
|
May 8, 1999
[Early recognition of prostate carcinoma. Initial results of a prospective multicenter study in Germany. Project Group for Early Detection DGU-BDU Laboratory diagnosis Professional Circle]
H J Luboldt, J E Altwein, K H Bichler, et al.
Molecular Cancer Research : MCR
|
April 28, 2023
Desmoglein 2 Functions as a Receptor for Fatty Acid Binding Protein 4 in Breast Cancer Epithelial Cells
Dongmei Chen, Keith M Wirth, Scott Kizy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 26, 1999
Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer
S D Baker, M Wirth, P Statkevich, et al.
Aktuelle Urologie
|
May 31, 2006
[Interdisciplinary recommendations concerning the therapy for hormone-refractory prostatic carcinoma]
K Miller, K Becker, F Finke, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 26, 1998
Dose intensification of epidoxorubicin and cyclophosphamide in metastatic breast cancer: a randomised study with two schedules of granulocyte-macrophage colony stimulating factor
H Stöger, H Samonigg, M Krainer, et al.
Nature Nanotechnology
|
July 17, 2020
COVID-19 vaccine development and a potential nanomaterial path forward
Matthew D Shin, Sourabh Shukla, Young Hun Chung, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
October 30, 1998
A His19 to Ala mutant of melanoma growth-stimulating activity is a partial antagonist of the CXCR2 receptor
D L Baly, R Horuk, D G Yansura, et al.
Page
of 30
Search research articles
Search
Showing results (271-280 of 293) with videos related to
Sort By:
Page
of 30
Hepatobiliary Surgery and Nutrition
|
June 9, 2020
Systemic therapy without radiation may be appropriate as neoadjuvant therapy for localized pancreas cancer
Scott Kizy, Ariella M Altman, Keith M Wirth, et al.
Annals of Surgery
|
April 1, 2020
Bariatric Surgery is Associated With Decreased Progression of Nonalcoholic Fatty Liver Disease to Cirrhosis: A Retrospective Cohort Analysis
Keith M Wirth, Adam C Sheka, Scott Kizy, et al.
Urology
|
August 8, 2001
Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression
M Wirth, C Tyrrell, M Wallace, et al.
Der Urologe. Ausg. A
|
May 8, 1999
[Early recognition of prostate carcinoma. Initial results of a prospective multicenter study in Germany. Project Group for Early Detection DGU-BDU Laboratory diagnosis Professional Circle]
H J Luboldt, J E Altwein, K H Bichler, et al.
Molecular Cancer Research : MCR
|
April 28, 2023
Desmoglein 2 Functions as a Receptor for Fatty Acid Binding Protein 4 in Breast Cancer Epithelial Cells
Dongmei Chen, Keith M Wirth, Scott Kizy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 26, 1999
Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer
S D Baker, M Wirth, P Statkevich, et al.
Aktuelle Urologie
|
May 31, 2006
[Interdisciplinary recommendations concerning the therapy for hormone-refractory prostatic carcinoma]
K Miller, K Becker, F Finke, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 26, 1998
Dose intensification of epidoxorubicin and cyclophosphamide in metastatic breast cancer: a randomised study with two schedules of granulocyte-macrophage colony stimulating factor
H Stöger, H Samonigg, M Krainer, et al.
Nature Nanotechnology
|
July 17, 2020
COVID-19 vaccine development and a potential nanomaterial path forward
Matthew D Shin, Sourabh Shukla, Young Hun Chung, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
October 30, 1998
A His19 to Ala mutant of melanoma growth-stimulating activity is a partial antagonist of the CXCR2 receptor
D L Baly, R Horuk, D G Yansura, et al.
Page
of 30